Oligometastatic skin melanoma: molecular-genetic characteristics and the effectiveness of surgical intervention
- 作者: Telegin A.A.1,2, Prozorenko E.V.1,2, Samoylenko I.V.1, Sevyan N.V.1,2
-
隶属关系:
- N.N. Blokhin National Medical Research Center of Oncology
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- 期: 卷 28, 编号 4 (2023)
- 页面: 197-203
- 栏目: Reviews
- URL: https://journals.rcsi.science/1028-9984/article/view/266644
- DOI: https://doi.org/10.17816/onco628266
- ID: 266644
如何引用文章
详细
“Oligometastatic” represents a so-called transitional stage between localized and disseminated process. The process itself is characterized by the presence of a primary tumor and a limited number of distant solitary metastases. The disease progression in oligometastatic cancer is slower compared to the massive dissemination, and the prognosis is more favorable. Oligometastatic process has been described in many malignancies, including melanoma, lung cancer, breast cancer, and others. This article focuses on oligometastatic melanoma and the role of surgical treatment in this scenario of disease progression.
One of the early theories of oligometastatic cancer was proposed in 1995. According to this theory, malignant neoplasms first develop as a single focus of initial (primary) tumor, followed by solitary involvement of distant tissues and organs (oligometastatic phase), and later progress to full dissemination and massive spread throughout the body. Weak points of this theory became evident as clinical practice showed that in some patients, the oligometastatic form of the disease did not progress to systemic dissemination, indicating that oligometastasis in this patient cohort was not an intermediate stage of disease development, but rather a separate form of tumor progression.
Another theory, encompassing the concept of oligometastasis, suggests that tumor malignancy is inherently a disseminated process, and the primary tumor and primary (solitary) oligometastases are simply the first detectable foci large enough to be visualized by diagnostic methods. However, similar to the previous theory, this approach fails to explain prolonged periods (or even constant presence) of oligometastatic disease in specific patient cohorts.
The modern understanding of the cause of oligometastasis is complex and consists of several statements. It is based on diverse molecular and genetic characteristics of malignant neoplasms, even within the same nosological entity and histological subtype. For metastatic process to take place, tumor cells must possess certain characteristics such as loss of adhesion, increased invasiveness, migratory capacity, and the ability to adapt and thrive in new microenvironments.
This article emphasizes the importance of surgical treatment in cases of oligometastatic disease and provides information on the current understanding of the mechanisms underlying this process.
作者简介
Alexander Telegin
N.N. Blokhin National Medical Research Center of Oncology; I.M. Sechenov First Moscow State Medical University (Sechenov University)
编辑信件的主要联系方式.
Email: dock996@bk.ru
ORCID iD: 0009-0009-1826-8850
SPIN 代码: 9139-2916
俄罗斯联邦, Moscow; Moscow
Evgeny Prozorenko
N.N. Blokhin National Medical Research Center of Oncology; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: prozorenko_e_v@staff.sechenov.ru
ORCID iD: 0000-0001-8880-1758
SPIN 代码: 1177-8997
MD, Cand. Sci. (Medicine)
俄罗斯联邦, Moscow; MoscowIgor Samoylenko
N.N. Blokhin National Medical Research Center of Oncology
Email: i.samoylenko@ronc.ru
ORCID iD: 0000-0001-7150-5071
SPIN 代码: 3691-8923
MD, Cand. Sci. (Medicine)
俄罗斯联邦, MoscowNadezhda Sevyan
N.N. Blokhin National Medical Research Center of Oncology; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: sevyan_n_v@staff.sechenov.ru
ORCID iD: 0000-0001-5841-7480
SPIN 代码: 1404-7422
MD, Cand. Sci. (Medicine)
俄罗斯联邦, Moscow; Moscow参考
- Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. doi: 10.1200/JCO.1995.13.1.8
- Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6(11):8491–8524. doi: 10.18632/oncotarget.3455
- Fisher B. Laboratory and clinical research in breast cancer — a personal adventure: the David A. Karnofsky memorial lecture. Cancer research. 1980;40(11):3863–3874.
- Foster CC, Pitroda SP, Weichselbaum RR. Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease. The Cancer Journal. 2020;26(2):96–99. doi: 10.1097/PPO.0000000000000434
- Mittal V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol. 2018;13:395–412. doi: 10.1146/annurev-pathol-020117-043854
- Pedri D, Karras P, Landeloos E, Marine JC, Rambow F. Epithelial-to-mesenchymal-like transition events in melanoma. The FEBS Journal. 2022;289(5):1352–1368. doi: 10.1111/febs.16021
- Tang Y, Durand S, Dalle S, Caramel J. EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment. Cancers. 2020;12(8):2154. doi: 10.3390/cancers12082154
- Al Ghamdi H, Dhont J, Krayem M, et al. The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease. Cancers. 2022;14(8):2046. doi: 10.3390/cancers14082046
- Urbanski A, Minnemann J, Mauch C, et al. Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysis. Langenbecks Arch Surg. 2023;408(1):53. doi: 10.1007/s00423-023-02804-9
- Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–1835. doi: 10.1056/NEJMoa1709030
- Ch’ng S, Uyulmaz S, Carlino MS, et al. Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. Eur J Cancer. 2021;153:8–15. doi: 10.1016/j.ejca.2021.04.037
- Thompson JF, Faries MB, Friedman EB, Lee JE, Balch CM. Surgical Management of Distant Melanoma Metastases. In: Balch C, et al. Cutaneous Melanoma. Springer; 2020. doi: 10.1007/978-3-030-05070-2_64
- Faries MB, Mozzillo N, Kashani-Sabet M, et al. Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. Ann Surg Oncol. 2017;24(13):3991–4000. doi: 10.1245/s10434-017-6072-3
- Livingstone E, Zimmer L, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomized, double-blind, phase 2 trial. Lancet. 2022;400(10358):1117–1129. doi: 10.1016/S0140-6736(22)01654-3
- Feng R, Oermann EK, Shrivastava R, et al. Stereotactic Radiosurgery for Melanoma Brain Metastases: A Comprehensive Clinical Case Series. World Neurosurg. 2017;100:297–304. doi: 10.1016/j.wneu.2017.01.014
- Leung AM, Hari DM, Morton DL. Surgery for Distant Melanoma Metastasis. Cancer J. 2012;18(2):176–184. doi: 10.1097/PPO.0b013e31824bc981
- Aleshin VA, Bekyashev AH, Belov DM, et al. Individualization of treatment of patients with cerebral metastases of malignant tumors. prognostic scale tuns. Malignant tumours. 2017;7(4):48–52. EDN: LXCJCN doi: 10.18027/2224-5057-2017-7-4-48-52
- Prozorenko EV, Karakhan VB, Bekyashev AKh, et al. Surgical tactics regarding cerebral metastases with hemorrhages. Head and Neck Tumors (HNT). 2015;5(1):8–14. EDN: TWERVV doi: 10.17650/2222-1468-2015-1-8-14
补充文件
